key: cord-0015020-7ufon0i8
authors: Pujadas, Elisabet; Chaudhry, Fayzan; McBride, Russell; Richter, Felix; Zhao, Shan; Wajnberg, Ania; Nadkarni, Girish; Glicksberg, Benjamin S; Houldsworth, Jane; Cordon-Cardo, Carlos
title: SARS-CoV-2 viral load predicts COVID-19 mortality
date: 2020-08-06
journal: Lancet Respir Med
DOI: 10.1016/s2213-2600(20)30354-4
sha: 031fc91a74394d974d44b371eb396f156d2c0a1d
doc_id: 15020
cord_uid: 7ufon0i8

nan

www.thelancet.com/respiratory Vol 8 September 2020 e70

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection platforms currently report qualitative results. However, technology based on RT-PCR allows for calculation of viral load, which is associated with transmission risk and disease severity in other viral illnesses. 1 Viral load in COVID-19 might correlate with infectivity, disease phenotype, morbidity, and mortality. To date, no studies have assessed the association between viral load and mortality in a large patient cohort. [2] [3] [4] To our knowledge, we are the first to report on SARS-CoV-2 viral load at diagnosis as an independent predictor of mortality in a large hospitalised cohort (n=1145). We prospectively evaluated nasopharyngeal swab samples for SARS-CoV-2 by real-time RT-PCR (Roche cobas 6800; Roche, Basel, Switzerland). Positive samples were assessed by a laboratory-developed quantitative RT-PCR test approved for clinical use 5 and viral loads were calculated with standard curves (full method provided in the appendix [pp 1-2]).

Viral loads for symptomatic, hospitalised patients who tested positive for SARS-CoV-2 were measured on samples collected between March 13 and May 4, 2020, that tested positive on both platforms at diagnosis. Only patients with complete survival data (discharged from or died in hospital) were included in our analysis (n=1145). Mean age was 64·6 years (SD 17·5), with 651 (56·9%) male patients, and a self-reported racial distribution of 357 (31·2%) African American patients, 335 (29·3%) white patients, 42 (3·7%) Asian patients, 375 (32·8%) patients of other race, and 36 (3·1%) patients of unknown race. The overall mean log 10 viral load was 5·6 copies per mL (SD 3·0), and median log 10 viral load was 6·2 copies per mL (IQR 3·0-8·0). Mean log 10 viral load significantly differed between patients who were alive (n=807; mean log 10 viral load 5·2 copies per mL [SD 3]) versus those who had died (n=338; 6·4 copies per mL [2·7]) by the end of the study period.

A Cox proportional hazards model adjusting for age, sex, asthma, atrial fibrillation, coronary artery disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, heart failure, hypertension, stroke, and race yielded a significant independent association between viral load and mortality (hazard ratio 1·07 [95% CI 1·03-1·11], p=0·0014; appendix p 3), with a 7% increase in hazard for each log transformed copy per mL. A univariate survival analysis revealed a significant difference in survival probability between those with high viral load (defined as being greater than the overall mean log 10 viral load of 5·6 copies per mL) and those with low viral load (p=0·0003; appendix p 4), with a mean followup of 13 days (SD 11) and a maximum follow-up of 67 days.

Early risk stratification in COVID-19 remains a challenge. Here, we show an independent relationship between high viral load and mortality. Transforming qualitative testing into a quantitative measurement of viral load will assist clinicians in risk-stratifying patients and choosing among available therapies and trials. Viral load might also affect isolation measures on the basis of infectivity. Future work will address SARS-CoV-2 viral load dynamics and the quantitative relationship with neutralising antibodies, cytokines, preexisting conditions, and treatments received, among other covariates, as we develop integrative algorithms for risk prediction.

GN reports grants, personal fees, and non-financial support from Renalytix AI, non-financial support from Pensieve Health, and personal fees from AstraZeneca, BioVie, Gerson Lehrman Group, and Reata, outside of the submitted work. All other authors declare no competing interests. EP and FC contributed equally to this work. 

Point-ofcare HIV viral load testing: an essential tool for a sustainable global HIV/AIDS response

Viral load of SARS-CoV-2 in clinical samples

Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratorydeveloped real-time RT-PCR test

Maurizio De Angelis/Science Photo Library Published Online

See Online for appendix